Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07465965 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
A Phase 1 study of Obesity and Overweight, sponsored by Shanghai World Leader Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07465965 is a Phase 1 study of Obesity and Overweight that is actively recruiting participants, run by Shanghai World Leader Pharmaceutical Co.. The registered enrollment target is 60 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07465965, a Phase 1 study of Obesity and Overweight, is actively recruiting participants, sponsored by Shanghai World Leader Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The specific aim of this study is to examine the Safety, Tolerability and Pharmacokinetic of Semaglutide Nasal Spray compared with placebo and positive control in Adult Overweight or Obese Participants.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide Nasal Spray
- DRUG Semaglutide Injection
Study Locations (1)
New Jersey
- Frontage Clinical Services, Inc. - Secaucus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-03-02 |
| Est. Completion | 2026-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07465965
The ClinicalTrials.gov registry entry for NCT07465965 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (93% lower). The listed sponsor is Shanghai World Leader Pharmaceutical Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07465965 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT07465965 about?
NCT07465965 is a clinical study titled "A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults". The specific aim of this study is to examine the Safety, Tolerability and Pharmacokinetic of Semaglutide Nasal Spray compared with placebo and positive control in Adult Overweight or Obese Participants.
What is the current status of trial NCT07465965?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2026-03-02. Estimated completion is 2026-08-30.
What conditions does trial NCT07465965 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07465965?
The interventions under investigation include: Placebo (DRUG), Semaglutide Nasal Spray (DRUG), Semaglutide Injection (DRUG).
Who is sponsoring clinical trial NCT07465965?
This trial is sponsored by Shanghai World Leader Pharmaceutical Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07465965 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.